Australia - English - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - mesalazine, quantity: 500 mg - tablet, enteric coated - excipient ingredients: sodium carbonate; glycine; povidone; microcrystalline cellulose; croscarmellose sodium; colloidal anhydrous silica; calcium stearate; hypromellose; methacrylic acid copolymer; purified talc; titanium dioxide; iron oxide yellow; macrogol 6000; basic butylated methacrylate copolymer - salofalk granules and tablets are indicated in the treatment of acute ulcerative colitis of mild to moderate severity, and for the maintenance of remission and/or the long term treatment of ulcerative colitis. treatment of acute episodes and maintenance of remission of crohn's ileitis and colitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - mesalazine, quantity: 1 g - tablet, enteric coated - excipient ingredients: povidone; microcrystalline cellulose; croscarmellose sodium; colloidal anhydrous silica; calcium stearate; hypromellose; methacrylic acid copolymer; purified talc; titanium dioxide; iron oxide yellow; macrogol 6000 - salofalk tablets are indicated in the treatment of acute episodes and maintenance of remission of: i. mild to moderate ulcerative colitis; and ii. crohn?s ileitis and colitis

Australia - English - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - mesalazine, quantity: 1000 mg - suppository, moulded - excipient ingredients: hard fat - treatment of ulcerative proctitis

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

dr. falk pharma uk ltd - mesalazine - suppository - 1gram

Ireland - English - HPRA (Health Products Regulatory Authority)

dr. falk pharma gmbh - mesalazine - suppository - 1 gram(s) - aminosalicylic acid and similar agents; mesalazine

Ireland - English - HPRA (Health Products Regulatory Authority)

dr. falk pharma gmbh - mesalazine - suppository - 250 milligram(s) - aminosalicylic acid and similar agents; mesalazine

Ireland - English - HPRA (Health Products Regulatory Authority)

imed healthcare ltd. - mesalazine - suppository - aminosalicylic acid and similar agents; mesalazine

Australia - English - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - mesalazine, quantity: 3000 mg - granules, modified release - excipient ingredients: aspartame; carmellose sodium; microcrystalline cellulose; citric acid; hypromellose; magnesium stearate; methylcellulose; povidone; colloidal anhydrous silica; simethicone; sorbic acid; purified talc; titanium dioxide; triethyl citrate; methacrylic acid copolymer; flavour - salofalk granules granules are indicated in the treatment of acute ulcerative colitis of mild to moderate severity, and for the maintenance of remission and/or the long term treatment of ulcerative colitis.

Israel - English - Ministry of Health

rafa laboratories ltd - mesalazine - suppositories - mesalazine 500 mg - mesalazine - mesalazine - treatment and prevention of ulcerative colitis and crohn's disease.

Israel - English - Ministry of Health

rafa laboratories ltd - mesalazine - suppositories - mesalazine 1000 mg - mesalazine - mesalazine - treatment and prevention of ulcerative colitis and crohn's disease.